key: cord-0929423-pqfn2eco
authors: Ghazvini, Kiarash; Keikha, Masoud
title: What is efficacy of BCG vaccination in protection from COVID-19 in European countries?
date: 2020-08-07
journal: nan
DOI: 10.1016/j.phclin.2020.08.001
sha: b5199a36dc0d26cab74c6571ed0d7f32a4ebc355
doc_id: 929423
cord_uid: pqfn2eco

nan

The Bacillus Calmette-Guérin (BCG) is a live attenuated vaccine which is recommends for neonates in countries with a high incidence of tuberculosis; the BCG vaccine has strongest nonspecific effects on immune-response particularly T cell-dependent immunity [1] . According to review of the literatures, the BCG has beneficial results in reduction of respiratory infections during various clinical trials; the BCG vaccination also protects from influenza A virus, herpes simplex virus type 2 (HSV2), yellow fever, mengovirus, as well as bladder cancer [2] [3] .

The BCG vaccine ameliorate induction of pro-inflammatory cytokines which is named as trained immunity; it can be influenced heterogeneous immune response by epigenetic reprogramming such as support of IL-1β, TNF-α and IL-6 against viral infection [2] [3] [4] . Recent, we are lives in pandemic era with COVID-19 which is caused by SARS-CoV 2. Moreover; it has been suggested several evidence for protection of BCG vaccination against COVID-19; for example, 1) BCG vaccinated neonates has more resistant to SARS-CoV 2 infection, 2) there is reduction in mortality rates in BCG implemented countries, 3) efficacy of BCG vaccine against viral respiratory infections [3-5]. In recently days, it has been suggested that the BCG vaccine ca be used for reduction of mortality caused by SARS-CoV 2 and protection of health-care workers against COVId-19. There are fourteen registered clinical trials for evaluation of BCG vaccine against COVID-19; but clinical trials studies taken more time.

We provided the present study to evaluate the clinical efficacy of BCG vaccination against SARS-CoV 2.

We obtained COVID-19 reported data from European countries using the worldometer (https://www.worldometers.info/coronavirus/) up to 20-July-2020. Subsequently, data converted between two groups using BCG World Atlas Database site (SARS-CoV2 in BCG recommended vs. Non-BCG recommended European countries. The abundance of total deaths and recovered cases were extracted in Table I . Also, we showed beneficial effects of BCG vaccination against COVID-19 by event rate and odds ratio.

We founded that there are 19 European COVID-19 registered data considered to regions with non-BCG implemented countries besides 29 countries with BCG implemented in Europe. The incidence of COVID-19 was higher in BCG implemented European countries; but the number of recovered cases (recovered from COVID-19) was higher in these countries as well as lower total deaths in comparison with non-BCG implemented European countries. There is significant reduction in number of total recovered cases in BCG implemented countries (OR: 2.970; 2.956-2.985 with 95% confidence intervals; P-Value: 0.001). Also, we showed that BCG vaccination can reduce mortality caused by SARS-CoV 2 (OR: 0.360; 0.357-0.364 with 95% confidence intervals; P-Value: 0.001).

In summary, the BCG vaccine has beneficial effects on development of immune-system. It has been suggested that the BCG vaccine has clinical benefit in protection from viral pneumonia due to efficacy of BCG vaccine in protection from respiratory tracts infections. In recently, there are numerous registered trials for evaluation of BCG vaccine against SARS-CoV 2. We provided novel evidence to show efficacy of BCG vaccine against SARS-CoV 2. We founded that the BCG vaccine was significantly reduced mortality caused by SARS-CoV 2. In addition, we showed that incidence of recovered cases was significantly increased in BCG implemented countries compared with non-BCG implemented European countries. However, we need further investigation and completion of clinical trials to confirmed our presented findings.

Bacille Calmette-Guérin (BCG) vaccination and COVID-19: scientific brief

BCG-induced trained immunity: can it offer protection against COVID-19?